On March 11, 2021 Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, reported that its data from multiple oncology programs will be presented at the upcoming American Association of Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting 2021, April 10-15 and May 17-21 (Press release, Ryvu Therapeutics, MAR 11, 2021, View Source [SID1234576549]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Data presented will include results from the RVU120 (SEL120), a CDK8/CDK19 inhibitor program, as well as data from small-molecule STING agonists and HPK1 inhibitor projects.
"We are very excited with the possibility to share data from our most advanced fully-owned oncology program – RVU120 (SEL120) – which is currently in Phase 1b clinical development for the treatment of acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (HRMDS). We made a lot of progress in translational research concerning RVU120 and we look forward to sharing it with the scientific community" – said Krzysztof Brzózka, Chief Scientific Officer at Ryvu Therapeutics.
"At the same time, we are pleased to present the most recent data from our two preclinical immuno-oncology projects, which we consider as very promising assets in our pipeline" – added Brzózka.
Details of the e-poster presentations are as follows:
Title: SEL120, a CDK8/CDK19 inhibitor, possesses strong multilineage differentiation potential in AML
Permanent Abstract Number: 1018
Title: New generation of STING agonists – development and characterization of a novel series of systemic immunomodulators with improved potency
Permanent Abstract Number: 1280
Title: Development and characterization of small molecule HPK1 inhibitors
Permanent Abstract Number: 1281
The e-poster website will be launched on Saturday, April 10, which is the first day of the AACR (Free AACR Whitepaper) Virtual Annual Meeting. All e-posters will be made available for browsing on this date through to June 21, 2021.
Additional information is available at on the AACR (Free AACR Whitepaper) conference website View Source
About AACR (Free AACR Whitepaper) Annual Meeting
The AACR (Free AACR Whitepaper) Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from population science and prevention, to cancer biology, translational, and clinical studies; to survivorship and advocacy—and highlights the work of the best minds in research and medicine from institutions all over the world.